Table 2.
Incidences of neoplasms in the control, AA, and AT/AU groups.
| Group | Event | Crude IR | Multivariate Cox’s HRa |
|---|---|---|---|
| Cancer | |||
| Control | 59,339 | 3.611 | 1 |
| AA groupb | 11,061 | 3.72798 | 1.043 (1.022,1.065) |
| AT/AU groupc | 1,349 | 4.25107 | 1.07 (1.013,1.129) |
| Oral cavity | |||
| Control | 912 | 0.054924 | 1 |
| AA group | 156 | 0.05201 | 0.953 (0.804,1.13) |
| AT/AU group | 17 | 0.052875 | 0.873 (0.54,1.411) |
| Esophagus | |||
| Control | 440 | 0.026496 | 1 |
| AA group | 69 | 0.023002 | 0.882 (0.684,1.137) |
| AT/AU group | 5 | 0.015549 | 0.505 (0.209,1.219) |
| Stomach | |||
| Control | 7,878 | 0.47504 | 1 |
| AA group | 1,317 | 0.43958 | 0.939 (0.886,0.996) |
| AT/AU group | 156 | 0.48584 | 0.907 (0.774,1.063) |
| Colorectal | |||
| Control | 9,986 | 0.60229 | 1 |
| AA group | 1,653 | 0.55185 | 0.929 (0.882,0.979) |
| AT/AU group | 217 | 0.67619 | 0.979 (0.856,1.12) |
| Liver | |||
| Control | 4,485 | 0.27026 | 1 |
| AA group | 764 | 0.25484 | 0.967 (0.896,1.044) |
| AT/AU group | 74 | 0.23027 | 0.761 (0.605,0.958) |
| Biliary tract | |||
| Control | 1,094 | 0.065886 | 1 |
| AA group | 189 | 0.063012 | 0.974 (0.834,1.136) |
| AT/AU group | 32 | 0.099541 | 1.205 (0.848,1.714) |
| Pancreas | |||
| Control | 2,815 | 0.16957 | 1 |
| AA group | 504 | 0.16807 | 1.007 (0.916,1.107) |
| AT/AU group | 60 | 0.18668 | 0.936 (0.725,1.209) |
| Larynx | |||
| Control | 275 | 0.01656 | 1 |
| AA group | 46 | 0.015335 | 0.942 (0.689,1.287) |
| AT/AU group | 2 | 0.00622 | 0.33 (0.082,1.326) |
| Lung | |||
| Control | 4,122 | 0.24837 | 1 |
| AA group | 753 | 0.25117 | 1.028 (0.951,1.111) |
| AT/AU group | 95 | 0.29565 | 1 (0.816,1.226) |
| Kidney | |||
| Control | 1,346 | 0.08107 | 1 |
| AA group | 232 | 0.07735 | 0.949 (0.826,1.091) |
| AT/AU group | 34 | 0.10576 | 1.164 (0.828,1.636) |
| Thyroid | |||
| Control | 15,554 | 0.93933 | |
| AA group | 3,276 | 1.09588 | 1.165 (1.122,1.21) |
| AT/AU group | 406 | 1.26818 | 1.332 (1.207,1.47) |
| Breast | |||
| Control | 8,124 | 0.99083 | 1 |
| AA group | 1,430 | 0.96254 | 0.98 (0.926,1.036) |
| AT/AU group | 184 | 1.19358 | 1.122 (0.969,1.298) |
| Cervix | |||
| Control | 1,910 | 0.23247 | 1 |
| AA group | 332 | 0.22301 | 0.97 (0.863,1.09) |
| AT/AU group | 40 | 0.25872 | 1.065 (0.778,1.457) |
| Ovary | |||
| Control | 1,551 | 0.18874 | 1 |
| AA group | 272 | 0.18268 | 0.977 (0.859,1.112) |
| AT/AU group | 35 | 0.22636 | 1.107 (0.792,1.548) |
| Uterus | |||
| Control | 1,100 | 0.13383 | 1 |
| AA group | 167 | 0.11214 | 0.849 (0.721,0.999) |
| AT/AU group | 29 | 0.18753 | 1.262 (0.872,1.825) |
| Testis | |||
| Control | 160 | 0.019082 | 1 |
| AA group | 24 | 0.015893 | 0.837 (0.545,1.285) |
| AT/AU group | 4 | 0.023975 | 1.24 (0.46,3.344) |
| Prostate | |||
| Control | 2,091 | 0.24953 | 1 |
| AA group | 474 | 0.31412 | 1.259 (1.139,1.391) |
| AT/AU group | 61 | 0.36592 | 1.243 (0.963,1.604) |
| Bladder | |||
| Control | 1,116 | 0.067212 | 1 |
| AA group | 243 | 0.081022 | 1.216 (1.059,1.397) |
| AT/AU group | 26 | 0.080872 | 1.024 (0.694,1.512) |
| Nerve | |||
| Control | 923 | 0.055587 | 1 |
| AA group | 181 | 0.060348 | 1.087 (0.927,1.275) |
| AT/AU group | 25 | 0.077766 | 1.287 (0.865,1.916) |
| Skin | |||
| Control | 212 | 0.012766 | 1 |
| AA group | 42 | 0.014001 | 1.094 (0.785,1.524) |
| AT/AU group | 2 | 0.00622 | 0.417 (0.103,1.677) |
| Lymphoma | |||
| Control | 1,295 | 0.07799 | 1 |
| AA group | 234 | 0.07802 | 1.003 (0.873,1.153) |
| AT/AU group | 37 | 0.1151 | 1.361 (0.981,1.887) |
| Multiple myeloma | |||
| Control | 351 | 0.021136 | 1 |
| AA group | 68 | 0.022669 | 1.089 (0.84,1.412) |
| AT/AU group | 4 | 0.01244 | 0.483 (0.18,1.296) |
| Leukemia | |||
| Control | 826 | 0.049744 | 1 |
| AA group | 150 | 0.050009 | 1.006 (0.845,1.197) |
| AT/AU group | 15 | 0.046652 | 0.879 (0.528,1.466) |
Abbreviation: IR = incidence rate.
aMultivariate Cox’s regression analyses were adjusted for age and gender; diabetes mellitus, hypertension, and dyslipidemia status; and income level.
bThe AA group included patients with all types of alopecia areata except alopecia totalis/ alopecia universalis.
cThe AT/AU group included patients with alopecia totalis (ICD-10 L63.0) and alopecia universalis (ICD-10 L63.1).